Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk

Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk

The FDA is not recommending special cancer screenings for patients who have taken lorcaserin. The action follows an FDA alert in January about a possible elevated cancer risk based on its preliminary analysis of the study. Patients were also advised Feb. 13 to stop taking the drug and talk to their providers about alternative weight-loss medications and weight-management programs. They were also told to dispose of the pills at a drug take-back location if available, but if not, to mix them with an "unappealing substance" such as dirt, cat litter, or used coffee grounds; seal them in plastic bag; and put them in the trash. This article originally appeared on MDedge.com . Cite this: Lorcaserin (Belviq ) Withdrawn From US Market Due to Cancer Risk - Medscape - Feb 13, 2020.



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More